Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Clinical Trials and Human Subject Protections. 1, 2022), [link]. [14]

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

20 February 2022. Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Essay by I. war on drugs. 13 × 13.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

The Cannigma

DECEMBER 12, 2022

Using integration or psychotherapy along with these medicines allows patients to incorporate the positive effects permanently. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine.

History 119

History Microdosing Research and Development Clinical Trials 119

Veriheal

MAY 16, 2022

Following the successful experiment into the potential safety and efficacy of using ketamine for Parkinson’s patients, the university proceeded to sign an exclusive licensing partnership with Pharmather Inc. , Studying Ketamine Use for Parkinson’s Disease Patients. and Torsten Falk, Ph.D.,

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Project CBD

FEBRUARY 28, 2023

Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Available at: [link] Accessed October 17, 2022. Accessed October 17, 2022. February 2, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

APRIL 13, 2022

Apr 12, 2022, 07:00 ET. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Transaction expected to close in June 2022 , following anticipated shareholder approval. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Cannigma

JANUARY 13, 2023

The fact that migraine is now ranked as the second leading cause of years lived with disability illustrates the magnitude of the negative impact of the disease to patients and their ability to function normally. A 2019 retrospective review of 316 patients found that medical cannabis improved the experience of 88.3%

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

DECEMBER 28, 2021

We recently announced that we anticipate commencing our initial human trial for Epoladerm™ in the second quarter of 2022. We are on track to add accomplishments in 2022 and I remain confident that we have the significant financial strength to continue advancing our pipeline,” concluded Mr. Mack.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 26, 2021

Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022. Financial Results. Revenues for the nine months ended September 30, 2021 were $0.65

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

The Cannigma

FEBRUARY 1, 2023

Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. The answer: Maybe!

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

JULY 21, 2022

JULY 21, 2022. The comprehensive legislation would end federal cannabis prohibition by removing cannabis from the Controlled Substances Act; empower states to create their own cannabis laws; ensure federal regulation protects public health and safety; and prioritize restorative and economic justice .

Safety 52

Safety Legislation Clinical Trials Banking 52

Cannabis Law Report

DECEMBER 7, 2021

A full report of the anonymized, aggregate findings will be released in early 2022. Initial findings indicate a significant number of participants experienced clinically meaningful improvements, meaning they realized distinct and palpable improvements in quality of life through improvements in the respective health outcomes studied.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52